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Introduction: There is hardly any information regarding years of life lost due to cancer in Colombia.
Objective: To quantify total and average years of life lost due to cancer in Colombia, and to investigate 
changes in this burden between 1997 and 2012.
Materials and methods: We obtained sex-specific data on age distribution, remaining life expectancy, 
deaths due to specific cancers and total number of deaths from the Colombian Departamento 
Administrativo Nacional de Estadísticas. We calculated years of life lost based on each individual´s age 
at death and the remaining life expectancy at that age; as for average years of life, we divided these by 
the number of deaths due to specific cancers.
Results: The total number of cancer deaths increased by 33% between 1997 and 2012, comprising 15% 
of male and 20% of female deaths in the period 2010-2012. Total years of life lost due to cancer increased 
by 25.1% for males and 31.1% for females over the study period. The highest increases (>40%) were 
observed for colorectal, pancreas and kidney cancers in both sexes, for melanomas and bladder cancer 
in men, and for breast and ovarian cancer in women. Trends in average years of life lost were stable. 
Almost half (48-50%) of the years of life lost due to childhood cancers were due to leukemia.
Conclusion: Cancer is an increasing health burden in Colombia. The high average years of life lost 
illustrate the poor prognosis of the disease compared to other countries. Primary prevention, early 
detection, and adequate and timely treatments are needed to change this situation.
Key words: Neoplasms; potential years of life lost/trends; cost of illness; Colombia.
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Años de vida perdidos como medida de la carga de cáncer en Colombia, 1997-2012
Introducción. En Colombia existe escasa información sobre los años de vida perdidos por cáncer.
Objetivo. Determinar los años de vida perdidos por cáncer en Colombia y sus cambios entre 1997 
y 2012.
Materiales y métodos. La información por sexo y edad de la mortalidad por cáncer y la expectativa de 
vida en Colombia se obtuvo del Departamento Administrativo Nacional de Estadística, DANE. El cálculo 
de los años de vida perdidos por cáncer se basó en la edad de cada individuo al momento de morir y 
el número de años de vida esperados en esta edad. El promedio de años de vida perdidos se obtuvo 
dividiendo los años de vida perdidos por el número de muertes a causa de cánceres específicos.
Resultados. Entre 1997 y 2012, el número de muertes por cáncer aumentó 33 %: 15 % en hombres 
y 20 % en mujeres. En el mismo periodo, el total de años de vida perdidos por cáncer se incrementó en 
25,1 % en hombres y 31,1 % en mujeres. Los mayores incrementos (>40 %) se dieron en los cánceres de 
colon y recto, páncreas y riñón en ambos sexos, en los hombres, en el melanoma y el cáncer de vejiga, 
y en mujeres, en los cánceres de mama y ovario. El promedio de años de vida perdidos fue estable en 
el tiempo; 40 a 50 % de los años de vida perdidos por cáncer en niños se debió a leucemias.
Conclusiones. La carga de cáncer está aumentando en Colombia. El elevado promedio de años de vida 
perdidos demuestra que el pronóstico de la enfermedad es malo. La prevención primaria, la detección 
temprana, y el tratamiento adecuado y oportuno son necesarios para mejorar esta situación.
Palabras clave: neoplasias; años potenciales de vida perdidos/tendencias; costo de enfermedad; 
Colombia.
doi: http://dx.doi.org/10.7705/biomedica.v36i4.3207
548
Biomédica 2016;36:547-55de Vries E, Meneses MX, Piñeros M
From 1984 to 2008, overall cancer mortality rates 
decreased slightly in both sexes in Colombia (1). 
Around this same period (1985-2005), substantial 
demographic changes occurred in the country, 
including population growth (from 30.8 million to 
42.9 million inhabitants) and a rapidly increasing 
life expectancy: 4.3 years for men and 4.8 years for 
women (2). Many societal changes also occurred: 
a large healthcare reform led to greater health 
insurance coverage, which passed from 59% 
around year 2000 to 92% in 2012 (3), and security 
levels increased as violent deaths substantially 
reduced (4).
This combination of population growth and ageing 
of the population usually leads to a growing cancer 
burden, even with relatively stable or slightly 
decreasing cancer mortality rates (1,5). Although 
age-standardized mortality rates for cancer as a 
whole decreased slightly, the total annual number 
of cancer deaths among males increased between 
1984 and 1988 and between 2004 and 2008, from 
8,791 to 15,417 (175% increase), and among 
females from 9,624 to 15,847 (165% increase) (1). 
This apparent discrepancy between stable or even 
decreasing mortality rates with increasing number 
of cancer deaths can be explained by to population 
growth and ageing. Considering only the total 
number of cancer deaths, irrespective of age and 
cancer type, overlooks the fact that some cancers 
have a much heavier burden on society compared 
to others, because they occur more frequently 
among younger people.
Years of life lost (YLL) is a useful measure to take 
the age at death as well as the deaths at each age 
into account. The measure results from the sum 
of years of potential life lost by individuals in the 
population because of death by a certain disease, 
given their remaining life expectancy estimated by 
age and sex. The average years of life lost (AYLL) 
is the average number of years of life lost by each 
person dying from the disease under study.
Approximately 25-30% of YLL in western countries 
are attributed to cancers (6). While YLL depend 
strongly on absolute frequency of deaths, AYLL are 
mostly determined by the age at which the deaths 
occur. Together, these measures provide meaningful 
indicators for decisions regarding resource allo-
cations and design of prevention programs (7-9). 
They are also a useful base for comparison with 
other countries, and show the relative importance 
of different causes of death, taking into account the 
life expectancies of each population (10). Previous 
national and local Colombian studies used external 
life expectancy data from Japan or the Global 
Burden of Disease reports, considered as the 
“potential” life expectancy for other countries (11-
13). While using a standard “ideal life expectancy” 
provides a useful comparison with other countries, a 
major limitation is that it does not reflect the actual 
situation of years of life lost in a given country.
The purpose of this paper was to quantify YLL 
and AYLL due to cancer in general and to the 
most important cancer types in Colombia for the 
most recent periods with available data (up to 
2012), and to evaluate how this burden changed 
between 1997 and 2012 using the country’s life 
expectancy data.
Materials and methods
Data and corrections to the data
We used Colombia’s official mortality data and 
population denominators retrieved from the 
Departamento Administrativo Nacional de Estadís-
tica, DANE, and we analyzed the following cancer 
types as listed in the International Classification 
of Diseases, ICD-10: All cancers (C00-C96), oral 
cavity and pharynx (C00-C14), oesophagus (C15), 
stomach (C16), colorectum (C18-C20), pancreas 
(C25), bronchus and lung (C32-C34), breast 
(C50), cervix uteri (C53), ovary (C56), prostate 
(C61), brain and central nervous system (CNS) 
(C70-C72), leukemia (C91-C95), lymphomas (C81-
C85, C96), melanoma (C43), kidney (C64-C65) 
and bladder and urinary tract cancer (C66-68). We 
also considered all deaths combined, regardless 
of the cause of death.
We redistributed deaths without information on 
age proportionally by sex based on the age distri-
bution of the other cases in the same cause of 
death category during the corresponding period. 
Similarly, we redistributed deaths from unspecified 
uterine cancer (C55) according to the proportions 
of deaths for cervical cancer (C53) and cancer of 
the corpus uteri (C54) (14).
Analysis
We calculated annual YLL for the general popula-
tion (all ages) by period and sex summing up the 
number of cancer deaths in a certain age group with 
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the remaining life expectancy in that age for all age 
groups according to the method previously explained 
by Brustugun, et al. (6), using the following formula: 
To provide an estimate of the YLL due to cancer 
as a fraction of total YLL, we also calculated a 
hypothetical total YLL, based on the sum of the 
products of the total number of deaths per age 
group, multiplied by the estimated length of life on 
each age level. We applied this same method for 
childhood cancers (0- 14 years).
Life expectancy among Colombian population was 
calculated by age group, sex and time period 
according to DANE’s five-calendar year periods 
from 1997 to 2005, and from 2005 to 2015 (2). We 
calculated the number of deaths by cancer type, 
sex and age groups for the same periods based on 
the national mortality databases for the 1997-2012 
period as provided by DANE (1997-1999; 2000-
2004; 2005-2009; 2010-2012).
We calculated the AYLL by dividing the total YLL 
per cause by the total number of deaths due to this 
cause, and for each sex and period separately. 
We determined the changes in YLL and AYLL 
percentages over time as the percentage increase 
or decrease between 2010 and 2012 compared to 
the reference period (1997-1999).
Results
Overall number of cancer deaths
The total annual number of cancer deaths increased 
for both sexes in about 33%, from 12,292 in 1997-
1999 to 16,376 in 2010-2012 in males, and from 
12,687 to 17,001 in females. In the first period of 
the series (1997-1999), cancer comprised 12% of 
all male and 10% of all female deaths, while in the 
last period (2010-2012) it accounted for 15% and 
20% of male and female deaths, respectively.
Around 3-4% of all deaths occurring in children 
up to 14 years of age, was due to cancer, and this 
proportion was stable over time. The total number 
of cancer deaths in children (0 to 14 years) was 
1,749 in the period 1997-1999, which decreased to 
1,510 in 2010-2012.
Overall years of life lost and average years of 
life lost
In 1997-1999, a hypothetical 534,960 (239,626 
males; 295,334 females) years of life were lost 
due to cancer annually, and this figure increased 
to 687,540 (299,874 males; 387,666 females) in 
2010-2012 representing an overall increase of 
28.5%: 25.1% in males and 31.1% in females. In 
the same period, the Colombian population grew 
by 24,8% (from 38.6 million in 1997 to 48.2 million 
in 2012) (2).
Years of life lost and average years of life lost 
by cancer types
Whereas YLL for any cause of death decreased 
markedly between 1997 and 2012 (-12% for 
males, and -54% for females), in this same period 
they increased for cancer, with 25% in males 
and 31% in females. For the 2010-2012 period 
the three most common cancer causes of YLL in 
men were stomach cancer (49,907), lung cancer 
(41,871), and leukemia (29,908), while in women 
they were breast cancer (61,398), cervical cancer 
(40,165), and stomach cancer (30,210) (figure 1). 
In this same period, one cancer death in Colombia 
represented on average 25.7 years of life lost for 
men and 22.8 for women, though these estimates 
vary significantly between cancer types.
Virtually, all cancer types showed AYLL of 15 or 
more years, with the exception of prostate and 
bladder cancer in males. The highest AYLL in 
both sexes corresponded to cancers occurring 
predominantly at young ages: Leukemia (males: 
33.8, females: 36.2), cancers of the brain and 
central nervous system (males: 29.0, females: 
30.8) and lymphomas (2010-2012: males 24.5, 
females 24.6) (figure 2).
We observed the highest increase in YLL for both 
sexes in colorectal, pancreas and kidney cancers, 
all by more than 40%. For males, the most substan-
tial increases corresponded to pancreas, melanoma 
and bladder cancer, while in females, breast, 
ovarian and colorectal cancers had the largest 
increases (table 1).
AYLL trends remained fairly stable, except for very 
rare cancers such as male breast cancer; the few 
changes observed were generally towards lower 
AYLL. The largest reductions in AYLL were observed 
for cancers of the brain and central nervous system, 
melanomas, lymphomas and leukemia, where two 
or more years of life expectancy were gained (table 
1, figure 2).
Leukemia was the main cause of YLL for children 
(48-50% of YLL), followed by cancers of the central 
nervous system (15-16%), lymphomas (6-10%) 
and kidney cancers (3-4%), which were stable 
over time; these four cancer types explained 75% 
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Figure 2. Average years of life lost to cancer by sex and cancer types, Colombia, 1997-2012 
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Figure 1. Years of life lost by sex and cancer types, Colombia, 1997-2012.
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or more of childhood cancer deaths during the 
study period (figure 3). During this period, YLL for 
childhood cancers dropped substantially, mainly due 
to decreases in lymphoma- and leukemia-related 
YLL. YLL for childhood cancers of the central 
nervous system and kidney remained rather stable.
The AYLL were very similar for childhood cancer, 
regardless of the cancer type, varying from 67.0 for 
colorectal cancer to 72.9 years for kidney cancer 
(results not shown).
Discussion
According to our results, the contribution of cancer 
to the total YLL in Colombia (15-20%) was lower 
than the one reported for western countries (25-
30%) (6). Our estimates were also lower compared 
to the 2011 and 2015 Colombian studies produced 
by the Observatorio Nacional de Salud (ONS) 
(12,13) (table 2). Such differences are most likely 
due to the life expectancy tables of the Global 
Burden of Disease study used in ONS reports 
(12,13,15), which show higher life expectancy 
estimates, and, therefore, a higher number of 
YLL due to cancer. Although widely used and 
recommended, the disadvantage of Global Burden 
of Disease estimates is that they do not reflect the 
real number of years of life lost in local settings. 
Using optimal life expectancy gives a hypothetical 
number of life years lost, whereas in this study 
we were interested in the reality of the Colombian 
Table 1. Change in years of life lost (YLL) and average years of life lost (AYLL) between 1997 and 2012 by cancer type and sex
Cancer types Percentage of change in YLL, 1997-2012 Change in AYLL, 1997-2012 (years)
Males (%) Females (%) Males Females
C00-C14 Head and neck + 27 + 33 - 0.4 +   1.6
C15 Oesophagus +   4 -    6 - 0.5 -   0.5
C16 Gastric + 20 + 22 + 0.2 +   1.8
C18-C20 Colorectal + 84 + 76 - 0.9 -   0.2
C25 Pancreas + 63 + 57 - 0.4 -   0.2
C32-C34 Lung + 25 + 44 - 1.1 -   0.9
C43 Melanoma + 56 + 39 - 3.4 -   3.9
C50 Breast - 52 + 80 - 4.7 +      0
C53 Cervix* - +   7 +   0.7
C56 Ovarian - + 77 +   0.1
C61 Prostate + 39 - - 0.6
C64-C65 Kidney + 62 + 48 - 2.1 -   0.2
C67 Bladder + 56 + 38 - 0.5 -   0.5
C70-72CNS Tumours + 11 + 16 - 1.8 -   2.4
C81-C85 + C96 Lymphoma + 28 + 35 - 4.4 -   4.1
C91-C95 Leukemia + 10 + 16 - 4.9 -   4.8
C 00-96 All cancers + 25 + 31 - 1.2 -   0.5
Total deaths - 12 - 54 - 5.3 - 12.3
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Figure 3. Years of life lost for cancers occurring during childhood (under 15 years of age), 1997-2012 
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population. In addition, the ONS reports used 
1998-2011 data, and did not apply redistribution 
of cases with unknown age or unspecified uterine 
cancer cases (14) as we did following international 
recommendations, wich could account for the higher 
YLL in our study.
YLL among the Colombian female population 
decreased, but the AYLL by cancer type was higher, 
largely because of women’s longer life expectancy 
(78.5 years at birth in 2010-2012 versus 72.1 for 
males) (2). This is in line with the latest ONS study 
reporting neoplasms among the top three causes 
contributing to most YLL in females alone (12).
Breast and cervical cancer were very important 
contributors to female cancer mortality. Despite 
efforts to improve early detection and treatment of 
these cancers, YLL due to breast cancer increased 
substantially, with no reductions in AYLL; this 
indicates increasing number of breast cancer 
deaths with minimal improvements in age of death, 
as female life expectancy at birth increased by 3.6 
years (from 74.95 in 1997-99 to 78.54 in 2010-12).
Virtually all cancer types showed AYLL of 15 or 
more years, with the exception of prostate and 
bladder cancer, which for 2010-12 contributed 
11.3 and 13.7 years to the AYLL, respectively. 
In general, our results for AYLL were high when 
compared to international reports, which inform of 
less than 7 years AYLL for colorectal and breast 
cancer (USA), 1.8 for prostate cancer, and 13.8 
for lung cancer (6,7,16). In a Polish study, only 
male brain cancer and cervical cancer showed 
more than 10 years of life lost per death (AYLL 
10.7 and 10.2, respectively) (16).
Our figures, although not comparable with those 
from other countries due to differences in overall life 
expectancy and in the calculating methodologies, 
evidence the great disparity between estimates 
(less than 13.5 AYLL in the US compared to more 
than 15 years in Colombia, except for prostate and 
male bladder cancer), and confirm that cancer 
prognosis in our country is relatively poor. Breast 
cancer in the USA was responsible for 6.3 years of 
life lost per death, in Colombia this figure was 25.6 
years, illustrating the combined effect of a usually 
very late diagnosis of breast cancer and/or its more 
frequent occurrence. Indeed, there is evidence 
that in Bogotá only 12-30% of women with breast 
cancer were diagnosed at the early stages, and 
that delays are substantial both for diagnosis and 
initiation of treatment (17,18).
Despite a high prostate cancer incidence in 
Colombia (19), the AYLL due to this cancer was 
relatively low compared to other cancer types, 
though high when compared to other countries, 
which could be attributed to the advanced age at 
diagnosis, and to its relatively good prognosis.
Leukemia frequently occurs amongst children 
and has a poor prognosis in Colombia, explaining 
the very high AYLL encountered for this cancer 
type. Not surprisingly, all childhood cancer deaths 
(all cancer types) had an AYLL of around 70 
years, because of the very similar remaining life 
expectancy during childhood.
The YLL of leukemia increased among children and 
among all age groups, while AYLL of all cancers 
decreased substantially, indicating more deaths or 
later ages of death. However, AYLL in childhood 
leukemia slightly increased (64.6 to 67.8 among 
girls, 72.0 to 73.9 among boys), possibly due to 
increases in life expectancy, which indicates that 
no much progress has been achieved despite the 
special efforts displayed by the government since 
2008 to reduce administrative delays (20-22). On 
the other hand, it could be attributed to an increase 
in the number of cases, as population-based survival 
estimates for childhood cancer show improve-
ments in survival even if it still remains poor in 
Colombia (20,22,23). Indeed, long-term data from 
Cali show slight increases in childhood incidence 
of leukemia and central nervous system cancers 
(24). We observed no progress at all regarding 
childhood cancers of the brain and central nervous 
system, or for kidney cancers. YLL for childhood 
leukemia were higher than for brain and central 
nervous system cancers, although this difference 
is decreasing; it is conceivable that if the actions 
to improve leukemia prognosis in Colombia are 
successful, these two other type of cancers will be 
the main cause of cancer deaths amongst children, 
similar to the situation observed in the USA (10).
Table 2. Years of life lost by cancer types according to our 
estimates and estimates by the Observatorio Nacional de 
Salud (ONS) (13)
Cancer types Our estimates ONS estimates 
Stomach 86,763 100,377
Lung and bronchus 73,446 81,055
Leukemia 58,226 74,152
Breast 61,398 67,425
Colorectal 42,866 61,133
Cervix uteri 51,340 49,296
Prostate 27,507 33,485
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Despite the fact that good methods exist for early 
detection of breast, cervical, prostate and colorectal 
cancer, all of these cancer types showed stable 
or increasing YLL and AYLL, reflecting the great 
potential for improvements in their early detection 
in Colombia.
Our AYLL for breast and cervical cancer were much 
higher (around 25 years) than previous national 
estimates for 2007 (with 14.4 YLL for breast 
and 14.6 for cervical cancer), probably due to 
differences in the life expectancy information used 
(25). In a study estimating the burden of disease for 
the Colombian department of Santander, stomach 
cancer appeared as the first cause of “healthy” 
life years lost in men, followed by leukemia and 
colorectal cancer, while for females the first causes 
were cervical, breast and stomach cancers (12). 
In contrast, in our study lung cancer was among 
the first causes in males, while in females the top 
causes were the same as in Santander. As smoking 
habits and lung cancer mortality vary heavily within 
Colombia (smoking prevalence was lower in 
Santander than the Colombian average) (26,27), 
regional YLL estimates will vary substantially as well. 
Moreover, the Santander study reported healthy life 
expectancy using life tables from Japan as source 
for remaining life expectancy, which are not compa-
rable to those we used, and this resulted in different 
life expectancies and, therefore, different YLL.
The observed YLL trends, with more than 40% 
increase in certain cancer types, are in line with the 
increasing life expectancy, and, perhaps, the recent 
efforts to diminish poverty rates in Colombia. This is 
in line with the fact that cancer types with increasing 
YLL (breast, colorectal, pancreas, kidney, bladder 
cancer and melanomas) are mostly related to a 
more “western” lifestyle and slowly replace the 
traditionally high burden of infection- and poverty-
related cancers, such as gastric and cervical can-
cers. The increasing proportion of cancer deaths in 
the total death toll in Colombia is due to population 
ageing, but also to diminishing number of deaths 
due to violence (from 0.1% to 0.03% over the 
study period).
Even though gastric cancer mortality rates have 
significantly decreased (1), YLL and AYLL have 
increased, implying that their diagnosis is very late. 
Anti-tobacco measures should be strengthened to 
further reduce the burden of lung- and other tobacco-
related cancers. Early detection and screening 
efforts, with a close and direct access to diagnosis 
and treatment of abnormal results, should be able 
to reduce breast, cervical and colorectal cancer 
mortality substantially. Even though interventions 
to improve survival in children with leukemia seem 
to be successful,  survival rates are still very poor. 
In Cali, for example, population-based data from 
the cancer registry showed rates of only 55% in the 
most recent diagnostic period (23).
We used national mortality data, generally con-
sidered to have acceptable quality and to be among 
the best within Central and South America (28), 
particularly after redistributing the cases of unknown 
age and “uterus, not specified” cases. The quality of 
the coding in death certificates has improved over 
time and, therefore, misclassification may have 
been a larger problem in earlier periods. Indeed, 
the proportion of deaths with unknown age reduced 
over time, supporting this hypothesis. However, 
stable estimates or trends allow us to conclude that 
misclassification has been relatively minor, and it 
does not hinder deriving general conclusions such 
as those arrived at in our study.
Contrary to several previous studies, we did not 
use an external population to provide the expected 
remaining years of life at death (life expectancy from 
life tables), but rather the period and sex-specific 
life tables provided for Colombia by DANE. The 
advantage of this method is that it provides the most 
realistic YLL and AYLL estimates, as they are based 
on the local real life tables for the corresponding 
periods. In this respect, we took into account the 
substantial increases in life expectancy among 
Colombian population in calculating the trends. 
However, these improvements in life expectancy 
may hide other improvements also achieved. If 
deaths in recent periods occurred at the same ages 
as before, more potential years of life would be 
lost and, therefore, the trend would be negative. 
Consequently, the stable trends observed may 
suggest an improvement, which is not apparent 
because of overall life expectancy improvement. 
Similarly, YLL increases in this study may not be so 
much a deterioration as a stabilization of the status 
quo, due to this increased general life expectancy, 
while AYLL decreases, mainly in leukemia, lym-
phomas, cancers of the central nervous system 
and melanomas (cancers ideally occurring at 
relatively young ages), actually mean even larger 
improvements regarding the average age at death. 
Indeed, in sensitivity analyses using 2010-2012 
life expectancy for all periods, AYLL increased in 
earlier periods (i.e., more years lost given higher 
life expectancy). Tendencies, however, remained 
the same (supplementary table, available in: doi: 
http://dx.doi.org/10.7705/biomedica.v36i4.3207)
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Together with cancer incidence, mortality and 
survival statistics, YLL and AYLL provide information 
on the burden of disease in a population. With 
increasing life expectancy and population size, 
the burden of cancer in Colombia is unsurprisingly 
also increasing. The AYLL was very high for many 
cancer types,  and although comparisons with other 
countries are difficult given their different popula-
tion structures, it is clear that primary or secondary 
prevention, early detection and more timely and 
adequate treatment can prevent many cancer 
deaths. The marked increases in YLL observed for 
colorectal, breast, ovarian and pancreatic cancer 
are worrisome and call for urgent preventive 
measures. Melanoma is another largely avoidable 
cause of death, while the lack of progress in AYLL 
for childhood leukemia also gives large room for 
improvement. Given population growth and aging 
in the country, there is need of more health workers 
specialized in oncology and preventive medicine. 
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Supplementary table 1. Comparison of life expectation in women and men
Women’s life expectation in the various periods
C00-14  
Head and  
neck
C15  
Oesophagus
C16  
Gastric
C18-20  
Colorectal
C25  
Pancreas
C32-34  
Lung
C43  
Melanoma
C50  
Breast
C53  
Cervix
C56  
Ovarian
C64-65  
Kidney
C67  
Bladder
C70-72CNS 
Tumours
C81-85 + C96  
Lymphoma
C91-95  
Leukaemia
C 00-96  
All cancers
Total deaths
YLL 1997-2000 2952,410 3681,08 30210,42 15804,114   8467,487 21994,758 1632,287 34022,757 40165,177 10700,113 2742,388 1597,357 11373,863   9061,263 24549,691 295334,250 4202427,085
2000-2005 3560,419 3782,712 33587,034 20168,376   9404,606 25557,096 2175,394 44323,528 44548,978 13617,96 3247,560 1912,842 13545,972 10807,444 26017,197 335795,327 2017080,434
2005-2010 4034,877 3692,056 36336,364 24742,259 11443,972 29674,828 2470,23 51994,238 44152,482 17115,136 3975,426 2180,66 14653,781 11932,644 26689,107 365498,150 1943224,322
2010-2015 3912,648 3461,647 36855,47 27838,215 13270 31574,650 2274,747 61398,457 42866,933 18987,063 4058,493 2204,867 13237,183 12271,323 28356,347 387665,861 1917656,786
AYLL 1997-2000     17,511     17,175       19,173       19,818       18,421       19,293     18,907       25,568       26,747       24,981     24,215     16,189       33,138       28,622       41,014         23,279           34,673
2000-2005     19,309     16,390       19,193       19,938       18,261       18,963     18,916       25,960       27,284       25,426     25,734     15,994       32,563       27,841       39,686         23,216           26,407
2005-2010     19,308     16,409       20,000       20,093       17,932       18,737     16,082       25,537       27,084       25,110     25,648     15,444       31,898       26,214       37,761         22,899           23,723
2010-2015     19,087     16,643       20,937       19,660       18,253       18,397     14,998       25,597       27,461       25,071     24,015     15,712       30,760       24,559         36,231           22,342
Women’s life expection for 2010-2012 applied to all periods
C00-14  
Head and  
neck
C15  
Oesophagus
C16  
Gastric
C18-20  
Colorectal
C25  
Pancreas
C32-34  
Lung
C43  
Melanoma
C50  
Breast
C53  
Cervix
C56  
Ovarian
C64-65  
Kidney
C67  
Bladder
C70-72CNS 
Tumours
C81-85 + C96  
Lymphoma
C91-95  
Leukaemia
C 00-96  
All cancers
Total deaths
YLL 1997-2000 3080,257 3846,503 31626,007 16541,087 8884,89 23110,026 1695,413 35839,79 42302,44 11268,727 2876,706 1667,35 11920,244 9496,522 25598,005 309890,672 4383842,989
2000-2005 3680,023 3912,95 34720,294 20847,937   9732,628 26451,748 2242,858 45841 46044,092 14078,836 3350,923 1977,26 13955,316 11145,955 26730,212 346920,725 2075219,184
2005-2010 4098,529 3751,354 36918,446 25140,198 11633,12 30163,248 2506,522 52849,258 44861,006 17395,238 4035,254 2215,2 14867,507 12114,66 27046,902 371290,920 1970501,142
2010-2015 3912,648 3461,647 36855,47 27838,215 13270 31574,650 2274,747 61398,457 42866,933 18987,063 4058,493 2204,867 13237,183 12271,323 28356,347 387665,861 1917656,786
AYLL 1997-2000     18,269 17,946       20,072       20,743       19,329       20,271     19,638       26,934       28,170       26,308     25,401     16,899       34,730       29,997       42,766         24,427           36,170
2000-2005     19,958 16,954       19,840       20,610       18,898       19,626     19,503       26,848       28,199       26,286     26,553     16,532       33,547       28,714       40,774         23,985           27,168
2005-2010     19,613 16,673       20,321       20,416       18,228       19,045     16,319          25,957       27,519       25,521     26,034     15,688       32,363       26,614       38,267         23,262           24,056
2010-2015     19,087 16,643       20,937        19,660       18,253       18,397     14,998       25,597       27,461       25,071     24,015     15,712       30,760       24,559       36,231         22,803           22,342
Men’s life expection for the corresponding periods
C00-14  
Head and  
neck
C15  
Oesophagus
C16  
Gastric
C18-20  
Colorectal
C25  
Pancreas
C32-34  
Lung
C43  
Melanoma
C50  
Breast
C61  
Prostate
C64-65  
Kidney
C67  
Bladder
C70-72CNS 
Tumours
C81-85 + C96  
Lymphoma
C91-95  
Leukaemia
C 00-96  
All cancers
Total deaths
YLL 1995-1999 4273,537 6145,291 41533,14 12766,285   6761,707 33628,896 1628,82 410,09 19804,58 3274,700 2447,13 13129,057 12565,992 27096,819 239625,691 3288627,668
2000-2004 5358,453 6744,064 46183,334 15031,143   7615,678 38456,362 2183,68 253,814 24217,064 3925,463 3103,94 15270,297 14240,310 28653,857 267075,215 3458992,683
2005-2009 5251,704 7058,63 48600,182 14050,306   9344,976 43189,548 2609,982 239,884 26354,504 3162,453 3679,796 15907,979 15487,092 29566,173 289478,641 3014243,484
2010-2012 5440,443 6408,437 49907,29 23501,472 11015,177 41871,474 2546,567 198,387 27507,463 5295,720 3810,347 14567,503 16045,427 29908,938 299873,804 2894751,430
AYLL 1995-1999     18,172     15,575       17,656       19,080       17,609       16,907     18,509   21,212        11,824     23,243     14,228       30,834       28,935       38,775         19,495           30,969
2000-2004     18,415     15,532       17,949       18,851       17,613       16,756     17,414   17,874        11,588     23,228     14,767       31,190       28,188       37,893         19,280           30,497
2005-2009     17,553     15,259       17,719       18,106       17,553       16,297     15,371   16,893        11,241     21,083     14,197       29,657       26,348       35,622         18,598           27,077
2010-2012     17,779     15,114       17,830       18,171       17,238       15,832     15,158   16,532        11,267     21,183     13,739       29,019       24,547       33,834         18,312           25,653
Men’s life expectation for 2010-2012 applied to all periods
C00-14  
Head and  
neck
C15  
Oesophagus
C16  
Gastric
C18-20  
Colorectal
C25  
Pancreas
C32-34  
Lung
C43  
Melanoma
C50  
Breast
C61  
Prostate
C64-65  
Kidney
C67  
Bladder
C70-72CNS 
Tumours
C81-85 + C96  
Lymphoma
C91-95  
Leukaemia
C 00-96  
All cancers
Total deaths
YLL 1995-1999 4383,802 6262,414 42534,93 13123,928 6922,48 34399,786 1674,427 422,213 19952,477 3389,472 2486,983 13709,541 13115,598 28538,670 246811,079 3444225,497
2000-2004 5399,167 6772,516 46483,356 15157,023   7659,994 38640,749 2206,52 255,546 24264,466 3975,702 3118,454 15583,659 14511,861 29454,937 270007,268 3541895,992
2005-2009 5268,441 7071,77 48743,652 14100,883   9368,844 43292,317 2619,484 240,37 26380,744 3177,432 3686,558 16052,662 15614,165 29936,417 290883,677 3044662,081
2010-2012 5440,443 6408,437 49907,29 23501,472 11015,177 41871,474 2546,567 198,387 27507,463 5295,720 3810,347 14567,503 16045,427 29908,938 299873,804 2894751,430
AYLL 1995-1999     18,640     15,872       18,082       19,615       18,027       17,294     19,028   21,839       11,912     24,058     14,459       32,198       30,201       40,838         20,080           32,435
2000-2004     18,555     15,598       18,066       19,009       17,715       16,836     17,596   17,996       11,611     23,525     14,836       31,830       28,725       38,952         19,492           31,228
2005-2009     17,609     15,287       17,771       18,171       17,597       16,336     15,427   16,927       11,253     21,183     14,223       29,927       26,564       36,068         18,688           27,350
2010-2012     17,779     15,114       17,830       18,171       17,238       15,832     15,158   16,532       11,267     21,183     13,739       29,019       24,547       33,834         18,312           25,653
